Development of novel drugs against an untreated common target in multiple cancers

APOBEC蛋白最近被认为是导致癌症的最重要原因，甚至超过了吸烟或紫外线辐射。由APOBEC驱动的基因突变不仅是许多常见癌症的起因和生长，而且是它们在癌症中的扩散和耐药性的发展。目前还没有针对这一基本癌症驱动因素的药物被批准或处于临床开发阶段。APOBEC Discovery有限公司（ADL）正在开发新的治疗方法来抑制这些蛋白质的有害活性，以创造一种全新的抗癌治疗方法。一种安全有效的apobecc抑制药物应该在许多常见癌症中具有广泛的活性：防止生长、扩散和治疗耐药性。它也可能有潜在的机会用于预防高危人群的癌症形成。ADL已经开发了一套主要的候选分子药物，有望在实验室中显示出对癌细胞的显著活性。该项目将促进体内模型概念验证的发展，使ADL能够为我们的主要候选药物生成安全性和有效性数据。这些数据将使ADL能够在首次人体研究之前优化后期临床前开发。在全球最畅销的抗癌药物中，只有一种被一家英国制药公司商业化。ADL的目标是这个重要的药物研究项目帮助癌症患者活得更长。

APOBEC proteins have been recently recognised as the most significant cause of cancer, even more so than smoking or UV radiation. The genetic mutations driven be APOBEC are not only the cause and growth of many common cancers, but also their spread and the development of drug treatment resistance in the cancer. There are currently no medical treatments approved or in clinical development targeting this fundamental cancer driver. APOBEC Discovery Limited (ADL) is developing novel treatments to inhibit the harmful activity of these proteins to create a completely new class of anti-cancer therapy. A safe and effective APOBEC-inhibiting drug should have a broad range of activity across a number of common cancers: preventing growth, spread and treatment resistance. It may also have potential opportunity to be utilised to prevent cancers forming in high-risk individuals. ADL has developed a set of lead candidate molecule drugs that are expected to show significant activity against cancer cells in the laboratory. This project will facilitate the development of proof of concept in in vivo models allowing ADL to generate safety and efficacy data for our lead drug candidates. This data will enable ADL to optimise late stage pre-clinical development prior to first human studies. Only one of the top selling cancer medicines globally is being commercialised by a UK pharmaceutical company. ADL's goal is that this significant drug research programme helps cancer patients live longer.